Advertisement
Canada markets closed

  • S&P/TSX

    21,639.10
    -59.01 (-0.27%)
     

  • S&P 500

    5,431.60
    -2.14 (-0.04%)
     

  • DOW

    38,589.16
    -57.94 (-0.15%)
     

  • CAD/USD

    0.7281
    +0.0001 (+0.02%)
     

  • CRUDE OIL

    78.49
    -0.13 (-0.17%)
     

  • Bitcoin CAD

    91,012.80
    +1,097.20 (+1.22%)
     

  • CMC Crypto 200

    1,406.17
    -11.70 (-0.83%)
     

  • GOLD FUTURES

    2,348.40
    +30.40 (+1.31%)
     

  • RUSSELL 2000

    2,006.16
    -32.75 (-1.61%)
     

  • 10-Yr Bond

    4.2130
    -0.0250 (-0.59%)
     

  • NASDAQ

    17,688.88
    +21.32 (+0.12%)
     

  • VOLATILITY

    12.66
    +0.72 (+6.03%)
     

  • FTSE

    8,146.86
    -16.81 (-0.21%)
     

  • NIKKEI 225

    38,814.56
    +94.09 (+0.24%)
     

  • CAD/EUR

    0.6798
    +0.0024 (+0.35%)
     

Enfusion (ENFN) Reports Q1 Earnings: What Key Metrics Have to Say

Zacks Equity Research
·2 min read

Enfusion, Inc. (ENFN) reported $48.05 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 17.3%. EPS of $0.06 for the same period compares to $0.03 a year ago.

The reported revenue represents a surprise of +0.80% over the Zacks Consensus Estimate of $47.67 million. With the consensus EPS estimate being $0.04, the EPS surprise was +50.00%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

ADVERTISEMENT

Here is how Enfusion performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenues- Platform subscriptions: $44.69 million versus the four-analyst average estimate of $44.29 million. The reported number represents a year-over-year change of +17.6%.

  • Revenues- Managed services: $3.18 million compared to the $3.22 million average estimate based on four analysts. The reported number represents a change of +15.8% year over year.

  • Revenues- Other: $0.19 million versus the four-analyst average estimate of $0.27 million. The reported number represents a year-over-year change of -18.8%.

View all Key Company Metrics for Enfusion here>>>

Shares of Enfusion have returned +2.2% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Enfusion, Inc. (ENFN) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research